Literature DB >> 1929246

Antimicrobial susceptibility and molecular epidemiology of beta-lactamase-producing, aminoglycoside-resistant isolates of Enterococcus faecalis.

S M Markowitz1, V D Wells, D S Williams, C G Stuart, P E Coudron, E S Wong.   

Abstract

beta-Lactamase-producing (BL+), aminoglycoside-resistant (AR) Enterococcus faecalis is endemic in our hospital, having caused widespread colonization and infection. Suitable therapy for infections caused by these organisms has been problematic. We compared the antimicrobial and bactericidal activities, by broth macrodilution and time-kill methods, of several antibiotics, alone and in combination, against BL+, AR isolates of E. faecalis and determined the transmissibility of antibiotic resistance markers. Ampicillin-sulbactam, imipenem, daptomycin, and ciprofloxacin were the most active antibiotics with MICs for 90% of isolates tested of 2, 1, 2, and 1 microgram/ml, respectively, against inocula of 10(3) and 10(5) CFU/ml. Little inoculum effect was noted with imipenem, vancomycin, daptomycin, or ciprofloxacin, while the addition of sulbactam to ampicillin partially inhibited the effect of the increased inoculum. Penicillin-sulbactam and ampicillin-sulbactam combinations in a 2:1 ratio were most frequently bactericidal (greater than or equal to 3-log10-unit decrease in bacterial titers at 24 h for 13 of 20 isolates), followed by daptomycin (8 of 20 isolates) and ciprofloxacin (2 of 20 isolates). Bactericidal activity was not demonstrated for imipenem or teicoplanin. beta-Lactamase production and aminoglycoside resistance were associated with a 60- to 65-MDa plasmid which was easily transferred to a plasmid-free E. faecalis recipient. The 840-bp beta-lactamase gene probe hybridized to purified plasmid DNA from BL+ donor isolates of E. faecalis and transconjugants but not from BL- isolates. Ampicillin-sulbactam and daptomycin (an investigational antibiotic) seem to be reasonable choices for the empiric therapy of presumed enterococcal infections in hospitals in which BL+, AR E. faecalis strains are isolated. Their use should ideally be supported by tests for bactericidal activity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1929246      PMCID: PMC284289          DOI: 10.1128/AAC.35.6.1075

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Restriction mapping and hybridization studies of a beta-lactamase-encoding fragment from Streptococcus (Enterococcus) faecalis.

Authors:  K K Zscheck; R Hull; B E Murray
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

2.  Comparison of two beta-lactamase-producing strains of Streptococcus faecalis.

Authors:  B E Murray; D A Church; A Wanger; K Zscheck; M E Levison; M J Ingerman; E Abrutyn; B Mederski-Samoraj
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

3.  Susceptibility and bactericidal activity studies of four beta-lactamase-producing enterococci.

Authors:  J E Patterson; M J Zervos
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

4.  Serious infection due to beta-lactamase-producing Streptococcus faecalis with high-level resistance to gentamicin.

Authors:  J E Patterson; S M Colodny; M J Zervos
Journal:  J Infect Dis       Date:  1988-11       Impact factor: 5.226

5.  Treatment of experimental endocarditis caused by a beta-lactamase-producing strain of Enterococcus faecalis with high-level resistance to gentamicin.

Authors:  R G Hindes; S H Willey; G M Eliopoulos; L B Rice; C T Eliopoulos; B E Murray; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

6.  Comparison of enterococcal and staphylococcal beta-lactamase plasmids.

Authors:  A R Wanger; B E Murray
Journal:  J Infect Dis       Date:  1990-01       Impact factor: 5.226

7.  Daptomycin (LY146032) treatment of experimental enterococcal endocarditis.

Authors:  L M Bush; J A Boscia; D Kaye
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

8.  beta-Lactamase production in experimental endocarditis due to aminoglycoside-resistant Streptococcus faecalis.

Authors:  M Ingerman; P G Pitsakis; A Rosenberg; M T Hessen; E Abrutyn; B E Murray; M E Levison
Journal:  J Infect Dis       Date:  1987-06       Impact factor: 5.226

9.  Antimicrobial resistance in nosocomial isolates of Staphylococcus haemolyticus.

Authors:  J W Froggatt; J L Johnston; D W Galetto; G L Archer
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

10.  Inducible, transferable resistance to vancomycin in Enterococcus faecalis A256.

Authors:  D M Shlaes; A Bouvet; C Devine; J H Shlaes; S al-Obeid; R Williamson
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

View more
  15 in total

Review 1.  Beta-lactamase-producing enterococci.

Authors:  B E Murray
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

2.  Enterococci: on the back burner but still simmering.

Authors:  George M Eliopoulos
Journal:  Curr Infect Dis Rep       Date:  2006-09       Impact factor: 3.725

3.  Chromosomal DNA restriction endonuclease digestion patterns of beta-lactamase-producing Enterococcus faecalis isolates collected from a single hospital over a 7-year period.

Authors:  P S Seetulsingh; J F Tomayko; P E Coudron; S M Markowitz; C Skinner; K V Singh; B E Murray
Journal:  J Clin Microbiol       Date:  1996-08       Impact factor: 5.948

4.  Molecular typing of ampicillin-resistant, non-beta-lactamase-producing Enterococcus faecium isolates from diverse geographic areas.

Authors:  S M Donabedian; J W Chow; J M Boyce; R E McCabe; S M Markowitz; P E Coudron; A Kuritza; C L Pierson; M J Zervos
Journal:  J Clin Microbiol       Date:  1992-11       Impact factor: 5.948

5.  Comparison of ampicillin-sulbactam with vancomycin for treatment of experimental endocarditis due to a beta-lactamase-producing, highly gentamicin-resistant isolate of Enterococcus faecalis.

Authors:  S R Lavoie; E S Wong; P E Coudron; D S Williams; S M Markowitz
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

6.  Clonal spread of vancomycin-resistant Enterococcus faecium between patients in three hospitals in two states.

Authors:  J W Chow; A Kuritza; D M Shlaes; M Green; D F Sahm; M J Zervos
Journal:  J Clin Microbiol       Date:  1993-06       Impact factor: 5.948

7.  Characterization of glycopeptide-resistant enterococci from U.S. hospitals.

Authors:  N C Clark; R C Cooksey; B C Hill; J M Swenson; F C Tenover
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

8.  Emergence and nosocomial transmission of ampicillin-resistant enterococci.

Authors:  J M Boyce; S M Opal; G Potter-Bynoe; R G LaForge; M J Zervos; G Furtado; G Victor; A A Medeiros
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

9.  Isolation of a beta-lactamase-producing, aminoglycoside-resistant strain of Enterococcus faecium.

Authors:  P E Coudron; S M Markowitz; E S Wong
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

10.  Overproduction of a penicillin-binding protein is not the only mechanism of penicillin resistance in Enterococcus faecium.

Authors:  I Klare; A C Rodloff; J Wagner; W Witte; R Hakenbeck
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.